This leads to weakened efficacy or differential side effects of regulatory mechanisms observed in animal models (e.g., FXR agonists improving mouse MASLD) in human clinical trials (e.g., pruritus or exacerbated cholestasis in some human patients). Here, NR1H4 is linked to cholestasis.